drugset / Trial / NCT03256864
Twice-daily Tacrolimus and Everolimus Convert to Once-daily Tacrolimus and Everolimus in Liver Transplant Recipient
RandomizedParallel-groupOpen-labelOther
Summary
It has been identified that nonadherence to immunosuppressant regimen may cause long-term graft failure and death in solid organ transplant recipients. Therefore, simplification of the immunosuppression regimen by reducing daily dosing frequency may improve long-term outcome. The investigators will examine pharmacokinetics and safety profiles of stable liver transplant recipients receiving twice-daily TAC with EVR (BID) regimen and then being converted to once-daily TAC with EVR (QD) regimen over a 6-month study period post-conversion.
Timeline
- Start
- 2016-01
- Primary completion
- 2019-06-30
- Completion
- 2020-05-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Everolimus | Small molecule | 1 mg | — |
| Subject | Everolimus | Small molecule | 2 mg | — |
| Subject | Tacrolimus | Small molecule | 0.1 mg/kg | — |
| Subject | Tacrolimus | Small molecule | 0.2 mg/kg | — |
Indications
No indication recorded.